The pilot, which launched in April, has evaluated 46 facilities using one-day inspectional assessments as the agency looks to make its resources more targeted and efficient.
The agreement expands access to antibody-drug conjugate technologies as both companies continue investing in biologics and cell and gene therapy manufacturing.
Join this session to learn how life sciences manufacturers are leveraging advanced flow measurement insights to improve reliability, maintain compliance, and deliver confidence across every batch, cleaning cycle, and critical process.
